Definium Therapeutics (NASDAQ:DFTX) Insider Sells $585,750.24 in Stock

Posted by Francis Steltz on Jun 29th, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the sale, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Definium Therapeutics Price Performance

DFTX stock opened at $44.95 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The company’s 50-day moving average is $24.59 and its 200-day moving average is $19.41. The stock has a market capitalization of $4.48 billion, a PE ratio of -18.05 and a beta of 2.37. Definium Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $47.01.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities research analysts expect that Definium Therapeutics, Inc. will post -2.29 EPS for the current fiscal year.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds have recently modified their holdings of DFTX. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after acquiring an additional 3,020 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Definium Therapeutics during the third quarter worth $107,000. Flagship Harbor Advisors LLC bought a new stake in Definium Therapeutics during the fourth quarter worth $117,000. Finally, Caxton Associates LLP purchased a new position in Definium Therapeutics in the third quarter worth $126,000. Institutional investors own 27.91% of the company’s stock.

Analyst Upgrades and Downgrades

DFTX has been the subject of a number of recent research reports. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Piper Sandler reiterated an “overweight” rating and set a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Robert W. Baird increased their price objective on Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 23rd. Finally, HC Wainwright lifted their target price on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Definium Therapeutics has an average rating of “Buy” and an average target price of $47.08.

Check Out Our Latest Stock Analysis on DFTX

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.